Introduction/Background Eosinophils, a subset of lymphocytes, apart from parasitic, helminthic, and allergic reactions, are also involved in carcinogenesis and its dissemination. In addition to having established molecular and prognostic indicators for endometrial cancer, readily accessible, fast, and inexpensive biomarkers are in high demand. In this study, we correlate eosinophilic ratios such as eosinophil lymphocyte ratio [ELR] and eosinophil neutrophil lymphocyte ratio [ENLR] with clinical, surgico-pathologic, and recurrence rates in endometrial cancer [EC].

Methodology A total of 35 proven endometrial cancer patients treated between January 2019 and March 2023 were analysed. After calculating preoperative ELR and ENLR, a cut-off of 0.1 for ELR and 0.06 for ENLR was applied. Participant’s clinical, surgical, and pathological characteristics were correlated with these ratios. A standard follow-up protocol was followed. If any recurrence was detected, it was also correlated to these ratios.

Results The association between ELR and ENLR ratios with clinical, surgical, and pathological parameters and recurrence was calculated using the chi-squared test and Fischer's exact test. Individuals with hypertension had significantly greater ENLR (p-value: 0.018) and ELR than normotensive (p-value: 0.024). Surgical parameters (adverse events, surgical complexity score) had no significant association. In comparison to grades 2 and 3, it was found that FIGO histological grade 1 had the highest median ENLR. Both ELR and ENLR had a significant association with recurrence (ELR = 0.03, ENLR = 0.001).

Conclusion In the present study, the predictors of recurrence in endometrial cancer were ENLR at a cut-off of 0.06 and ELR at a cut-off of 0.1. In summary, the results suggest that eosinophilic ratios (ELR and ENLR) may be useful in predicting the prognosis of endometrial cancer. To determine the prognostic value of these indices, more research with larger sample populations might be helpful.

Disclosures All the authors declare no conflicts of interest.